Vaikom Mahadevan

MD

Cardiologist

About me

Dr. Vaikom Mahadevan is a world-renowned expert in interventional cardiology for treating adult congenital heart disease (ACHD) and structural heart disease. He has extensive experience in performing adult congenital and transcatheter valve procedures, including replacing all four of the heart's valves. He also has a strong interest in intracardiac echocardiography (ultrasound imaging inside the heart).

Mahadevan's research interests include transcatheter valve implantation and pulmonary hypertension in ACHD.

Mahadevan earned his medical degree from Stanley Medical College in Chennai, India, and received further training in internal medicine and cardiology in the United Kingdom. He completed a fellowship in adult congenital heart disease and intervention at the Royal Brompton Hospital in London, followed by a fellowship in the same specialties at Toronto General Hospital.

Before joining UCSF, Mahadevan served as a cardiology consultant and interventionist at the Manchester Royal Infirmary, part of Central Manchester University Hospitals. He was director of the ACHD and transcatheter aortic valve replacement program in Manchester, and he directed the ACHD interventional program for northwestern England. He also established and led the adult congenital pulmonary hypertension service for this region.

  • Education

    Stanley Medical College, 1994

  • Residencies

    Doncaster, 1997

  • Fellowships

    Royal Brompton Hospital, Adult Congenital Heart Disease and Intervention, 2004

    Toronto General Hospital, Adult Congenital Heart Disease and Intervention, 2005

  • Academic Title

    Professor

Adult Congenital Heart Disease Clinic

535 Mission Bay Blvd. South
San Francisco, CA 94158

Decorative Caduceus

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary...

The purpose of this study is to evaluate the hypothesis that valve dysfunction of the Edwards Lifesciences SAPIEN 3 Transcatheter Heart Valve (THV) System is within the performance goal of 25% in subjects with a dysf...

Recruiting

Share